SCHEMBL4137311

SCHEMBL4137311

[O]c1cc(N2CCOCC2)ncn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.61
CYP2C19 P33261 2/20 0.58
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NPC1 O15118 4/20 0.49
ALDH1A1 P00352 2/20 0.49
ATM Q13315 1/20 0.49
PIK3CB P42338 1/20 0.48
PIK3CA P42336 1/20 0.47
RAB9A P51151 4/20 0.47
EGFR P00533 2/20 0.47
ERBB3 P21860 2/20 0.47
ABL1 P00519 1/20 0.46
BCR P11274 1/20 0.46
ELOVL1 Q9BW60 1/20 0.46
LRRK2 Q5S007 1/20 0.45
CYP1A2 P05177 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
EGLN2 Q96KS0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31110333 0.86 CYP2C19 (0.68) KMOCYP2C19HTTSMN1; SMN2NPC1
SCHEMBL807666 0.81 CYP2C19 (0.58) KMOCYP2C19HTTSMN1; SMN2NPC1
SCHEMBL18615749 0.79 KMO (0.58) KMOCYP2C19HTTSMN1; SMN2NPC1
SCHEMBL10272311 0.78 CYP2C19 (0.63) KMOCYP2C19HTTSMN1; SMN2NPC1
SCHEMBL18399273 0.78 CYP2C19 (0.58) KMOCYP2C19HTTSMN1; SMN2NPC1
SCHEMBL4953660 0.78 HRH4 (0.55) CYP2C19ALDH1A1CYP1A2MAPTCYP2C9
SCHEMBL4137318 0.78 KMO (0.61) KMOCYP2C19HTTSMN1; SMN2NPC1
SCHEMBL4462897 0.78 CYP2C19 (0.58) KMOCYP2C19HTTSMN1; SMN2NPC1
SCHEMBL10746440 0.78 CYP2C19 (0.58) KMOCYP2C19HTTSMN1; SMN2NPC1
SCHEMBL2570384 0.78 CYP2C19 (0.58) KMOCYP2C19HTTSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases BETSCHART CLAUDIA 2009-02-26 US disclosed
US-7452886-B2 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases NOVARTIS AG (CH) 2008-11-18 US disclosed
EP-1423391-B8 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2007-12-12 EP disclosed
EP-1423391-B1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2006-05-17 EP disclosed
US-20050054851-A1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases NOVARTIS AG (CH) 2005-03-10 US disclosed
EP-1423391-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES Novartis AG (CH) 2004-06-02 EP disclosed
WO-2003020721-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054851-A1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases CTSK, CTSS, CTSZ KMO 386/4885CYP2C19 1412/4885HTT 1803/4885
US-20090054467-A1 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases CTSK, CTSS, CTSZ KMO 386/4885CYP2C19 1412/4885HTT 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.